How would you treat a post menopausal woman with newly diagnosed PR positive, ER negative and Her 2 negative metastatic breast cancer with germ-line BRCA2 mutation?

Based on current evidence the outcome of patients with germline BRCA 1 or 2 mutation who developed breast cancer is similar to patients with breast cancer who do not carry germline BRCA mutations. I would use similar judgement in regards to decision for different systemic therapy as I would if the patient was BRCA 1 or 2 mutation negative, except that I have an additional choice of using PARP 1/2 inhibitor olaparib (and likely soon to come Talazoparib). If the patient is asymptomatic and has rel...